Focused On-demand Library for Ubiquilin-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9UHD9

UPID:

UBQL2_HUMAN

Alternative names:

Chap1; DSK2 homolog; Protein linking IAP with cytoskeleton 2; Ubiquitin-like product Chap1/Dsk2

Alternative UPACC:

Q9UHD9; O94798; Q5D027; Q9H3W6; Q9HAZ4

Background:

Ubiquilin-2, known by alternative names such as Chap1 and DSK2 homolog, plays a pivotal role in protein degradation pathways including the ubiquitin-proteasome system (UPS), autophagy, and the ER-associated protein degradation (ERAD) pathway. It targets misfolded or accumulated proteins for degradation, mediates autophagosome-lysosome fusion, and is involved in the maturation of the autophagy-related protein LC3.

Therapeutic significance:

Ubiquilin-2's involvement in Amyotrophic lateral sclerosis 15, a neurodegenerative disorder, underscores its therapeutic significance. Understanding the role of Ubiquilin-2 could lead to novel therapeutic strategies for treating this fatal paralysis, highlighting the importance of research into its functions and disease associations.